Buturovic, Ljubomir
Zheng, Hong
Tang, Benjamin
Lai, Kevin
Kuan, Win Sen
Gillett, Mark
Santram, Rahul
Shojaei, Maryam
Almansa, Raquel
Nieto, Jose Ángel
Muñoz, Sonsoles
Herrero, Carmen
Antonakos, Nikolaos
Koufargyris, Panayiotis
Kontogiorgi, Marina
Damoraki, Georgia
Liesenfeld, Oliver
Wacker, James
Midic, Uros
Luethy, Roland
Rawling, David
Remmel, Melissa
Coyle, Sabrina
Liu, Yiran E.
Rao, Aditya M.
Dermadi, Denis
Toh, Jiaying
Jones, Lara Murphy
Donato, Michele
Khatri, Purvesh
Giamarellos-Bourboulis, Evangelos J.
Sweeney, Timothy E.
Funding for this research was provided by:
Inflammatix Inc.
Article History
Received: 23 May 2021
Accepted: 23 December 2021
First Online: 18 January 2022
Competing interests
: LB, OL, JW, UM, RL, DR, MR, SC, and TES are employees of, and stockholders in, Inflammatix, Inc, which is developing the 6-mRNA score into a commercial assay, CoVerity™. PK is a shareholder and a consultant to Inflammatix, Inc. EJGB has received honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). The other authors declare no competing interests.